Patents Examined by Cecilia Tsang
-
Patent number: 7696312Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: GrantFiled: October 17, 2007Date of Patent: April 13, 2010Assignee: Ambrx, Inc.Inventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
-
Patent number: 7696163Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: GrantFiled: October 8, 2003Date of Patent: April 13, 2010Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn Bowe, Xi Chen
-
Patent number: 7696173Abstract: The present invention provides compositions and methods related to expression of protease inhibitors and variants thereof in bacterial species. The present invention further provides fusion nucleic acids, vectors, fusion polypeptides, and processes for obtaining the protease inhibitors.Type: GrantFiled: July 14, 2008Date of Patent: April 13, 2010Assignee: Danisco US Inc.Inventors: Katherine Collier, Grant Ganshaw, Hans De Nobel, Scott D. Power, Anita Van Kimmenade, Marc Kolkman, Jeffrey Miller, Brian Schmidt, Gudrun Vogtentanz, David Estell
-
Patent number: 7696167Abstract: A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.Type: GrantFiled: November 21, 2005Date of Patent: April 13, 2010Assignee: Astellas Pharma Inc.Inventors: Motoo Kobayashi, Satoshi Sasamura, Hideyuki Muramatsu, Yasuhisa Tsurumi, Shigehiro Takase, Kazuki Okada
-
Patent number: 7691805Abstract: The invention relates to compositions comprising a compound based on the general formula (I) R1-Arg-R2—NH—CH(R3)—CH2—NH—R4 ??(I) and a carrier, diluent or an excipient.Type: GrantFiled: November 10, 2005Date of Patent: April 6, 2010Assignee: Neobiotics ABInventors: Anders Grubb, Aftab Jasir, Claes Schalén, Franciszek Kasprzykowski, Regina Kasprzykowska
-
Patent number: 7691966Abstract: The present invention relates to a method for analyzing the interaction between HIF-1 peptide and VBC protein using fluorescence polarization, more precisely, a method for quantitative analysis of formation of HIF-1-VBC protein complex which is composed of the steps of 1) preparing a fluorescent probe by attaching a fluorescein to hydroxyproline containing HIF-1 peptide; 2) reacting the fluorescent probe with VBC protein; and 3) measuring the fluorescence polarization of the above reactant and then comparing the fluorescence polarization with that of the fluorescent probe itself to investigate the changes of fluorescence polarization; a method for screening an inhibitor of the binding of HIF-1 peptide and VBC protein using the above method; and a method for analyzing the activity of prolyl hydroxylase using the above method.Type: GrantFiled: December 6, 2005Date of Patent: April 6, 2010Assignee: Korea Institute of Science and TechnologyInventors: Eun Gyeong Yang, Hyun Ju Cho, Hyunsung Park
-
Patent number: 7691813Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.Type: GrantFiled: May 20, 2008Date of Patent: April 6, 2010Assignee: Eli Lilly and CompanyInventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
-
Patent number: 7691807Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.Type: GrantFiled: March 17, 2006Date of Patent: April 6, 2010Assignees: Centre National de la Recherche Scientifique (CNRS), ImmuPharma France SAInventors: Aude Violette, Jean-Paul Briand, Robert Zimmer, Gilles Guichard
-
Patent number: 7687460Abstract: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising the administration of WISP polypeptide. Optionally, the administration may be in combination with one or more cartilage agents (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of WISP polypeptide in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of WISP polypeptide.Type: GrantFiled: October 12, 2001Date of Patent: March 30, 2010Assignee: Genentech, Inc,Inventors: Luc Desnoyer, Ellen H. Filvaroff, Diane Pennica
-
Patent number: 7683034Abstract: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous cells is inhibited by the administration of the inhibitors of APN and/or of DP IV depending on the dose. Our invention shows that, for a therapy and for a prevention of dermatological diseases with sebaceous hyperproliferation and modified conditions of differentiation, the application of inhibitors of the above-mentioned enzymes and of corresponding pharmaceutical preparations and dosage forms thereof is suitable.Type: GrantFiled: March 7, 2003Date of Patent: March 23, 2010Assignee: IMTM GmbHInventors: Siegfried Ansorge, Harald Gollnick, Klaus Neubert, Christos Zouboulis, Jurgen Faust, Uwe Lendeckel, Dirk Reinhold, Robert Vetter
-
Patent number: 7682808Abstract: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.Type: GrantFiled: February 23, 2006Date of Patent: March 23, 2010Assignee: The Board of Trustees of the University of IllinoisInventors: James H. Morrissey, Stephanie A. Smith, Roberto Docampo, Nicola J. Mutch
-
Patent number: 7678760Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: GrantFiled: June 14, 2007Date of Patent: March 16, 2010Assignees: The Board of Trustees of the University of Illinois, Oklahoma Medical Research FoundationInventors: Jordan J. N. Tang, Arun K. Ghosh
-
Patent number: 7674768Abstract: The present invention provides, inter alia, convergent processes for preparing eptifibatide that involve coupling a 2-6 eptifibatide fragment to an activated cysteinamide residue to form a 2-7 eptifibatide fragment, attaching a mercaptopropionic acid residue to the 2-7 eptifibatide fragment through disulfide bond formation, coupling the peptide intramolecularly, and removing the protecting group, to form eptifibatide. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide, and novel compounds that are structurally similar to eptifibatide.Type: GrantFiled: April 8, 2005Date of Patent: March 9, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Guojie Ho, Antoinette D. Paone, Luciano Forni, Catherine De Tollenaere, Brice Bonnet, Christine Devijver
-
Patent number: 7674766Abstract: The invention provides a method to C-terminally label proteins in a complex sample and identify those proteins, e.g., using mass spectrometry.Type: GrantFiled: February 11, 2005Date of Patent: March 9, 2010Assignee: Cornell Research Foundation, Inc.Inventor: Samie R. Jaffrey
-
Patent number: 7671009Abstract: Oligopeptides and derivatives thereof, peptide analogs and derivatives thereof as well as pharmaceutically acceptable salts of these compounds, which correspond to general formula (I) wherein R1 represents H, —C(O)—R7, —SO2—R7, —C(O)—OR7 or —C(O)—N(R7)2 R2 represents, independent of one another, H or —(C1-C4)-alkyl, R3 and R6 represent, independent of one another, —(CH2)q—N(R1)R8 R4 and R5 represent, independent of one another, —CH2—OR2, —CH(CH3)OR8 or —CH2—CH2—OR8 R7 represents hydrogen, optionally substituted (C1-C19)-alkyl; optionally substituted (C1-C19)-alkenyl; phenyl-(C1-C4)-alkyl whose phenyl radical is optionally substituted with amino in the para position R8 represents H, —(C1-C4)-alkyl, —C(O)—R7, —C(O)—OR7, —C(O)—N(R7)2 or —SO2—R7 X represents oxygen (—O—) or —NH—; or XR7, with X=O, also represents the esters of ?-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7=H) m, n, p represent, independent of one another, zero or 1 and q in R3 and R6 represent, independent of one aType: GrantFiled: October 30, 2002Date of Patent: March 2, 2010Assignee: DSM IP Assets B.V.Inventors: Christian Ludin, Marc Heidl, Hugo Ziegler
-
Patent number: 7671095Abstract: Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.Type: GrantFiled: May 31, 2007Date of Patent: March 2, 2010Assignees: The Trustees of the Boston University, The Brigham and Women's Hospital, Inc.Inventors: Yolonda Colson, Solomon Azouz, Mark Grinstaff, Jesse Wolinsky, Aaron Griset
-
Patent number: 7671013Abstract: The present invention relates to the use of coagulation proteins and complexes thereof with anticoagulation proteins for the lysis of blood clots or other applications affected by accelerated plasmin production. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein, with or without being in complex with a serpin, comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.Type: GrantFiled: June 13, 2006Date of Patent: March 2, 2010Assignee: Canadian Blood Services, Inc.Inventor: Edward L. G. Pryzdial
-
Patent number: 7671032Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.Type: GrantFiled: January 28, 2005Date of Patent: March 2, 2010Assignee: Medivir ABInventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
-
Patent number: 7671029Abstract: Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formula Carrier-Linker-Peptide Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.Type: GrantFiled: April 15, 2004Date of Patent: March 2, 2010Assignee: ImmuPharma SAInventor: Robert H. Zimmer
-
Patent number: 7666834Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR6, —NH—SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy-carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optioType: GrantFiled: July 28, 2006Date of Patent: February 23, 2010Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Carl Erik Daniel Jönsson, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist, Dmitry Antonov, Lourdes Salvador Odén, Susana Ayesa Alvarez, Björn Olof Classon